PFE
Not a home run, but not a swing-and-miss either
Pfizer’s sigvotatug vedotin just got its latest test in the clinic, and the headline is basically: the drug didn’t win the race overall, but it found a faster lane in a subset of patients. In the Phase 3 SigVie-002 study, the antibody-drug conjugate missed its primary overall survival endpoint in previously treated advanced non-squamous non-small cell lung cancer.
That’s the bad news. The less-bad news? In patients who’d only had one prior line of systemic therapy — about two-thirds of the trial — the drug showed a more encouraging trend versus docetaxel for both overall survival and progression-free survival. In biotech land, that’s the difference between "pack it up" and "okay, maybe there’s a version of this story that still works."
Why Wall Street still cares
For investors, this is about optionality. Pfizer doesn’t need every pipeline asset to become a blockbuster, but it does need enough shots on goal to keep the post-COVID growth story from feeling like a hangover.
A few takeaways:
- The broad population result makes a clean label win harder.
- The earlier-line subgroup signal could shape future development strategy.
- Safety looked manageable, which at least keeps the door from slamming shut.
The biotech sequel is already in motion
Pfizer says it’s already testing the drug in another Phase 3 study, this time with pembrolizumab in first-line advanced NSCLC. So this isn’t the end credits — more like the midseason cliffhanger where the writers are clearly leaving themselves an escape hatch.
The company also said the result fits into its bigger oncology push, which has gotten a boost from the Seagen acquisition. Big picture: Pfizer’s cancer pipeline is still alive, but this readout reminds you that even giant pharma names have to live and die by the same harsh clinical scoreboard as everyone else.